PULSAR Radiation Plus IMSA101 Immunotherapy Trial in Oligoprogressive Cancers Terminated Early
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Summary
This Phase 2 trial tested whether adding IMSA101, an experimental immune stimulator, to a precision radiation technique called PULSAR combined with immune checkpoint inhibitors could help patients whose cancers had begun progressing in a limited number of sites after prior treatment. PULSAR delivers highly adaptive, ultra-fractionated stereotactic radiation designed to work synergistically with immunotherapy. IMSA101 is a STING agonist that activates innate immune sensing to potentially amplify anti-tumor immune responses. The trial enrolled only 16 patients across multiple centers before being terminated in late 2024. Because the trial was stopped early and only limited data are publicly available, conclusions about efficacy or safety cannot be drawn. The study reflects the broader push to convert radiation into an immune-sensitizing event rather than purely a local tumor ablation tool.
Detailed Summary
Cancer immunotherapy has transformed oncology, but many patients eventually experience oligoprogression — limited disease spread at a small number of sites while remaining controlled elsewhere. Managing oligoprogression effectively without abandoning a working systemic regimen is a key clinical challenge. This trial attempted to address that gap using a novel combination of precision radiation and immune activation.
The study was a Phase 2, open-label, multicenter, randomized trial sponsored by ImmuneSensor Therapeutics Inc. It compared PULSAR — personalized ultra-fractionated stereotactic adaptive radiotherapy — combined with immune checkpoint inhibitor (ICI) therapy alone versus the same regimen augmented by IMSA101. IMSA101 is an investigational STING pathway agonist, meaning it activates innate immune sensing machinery within tumors to potentially amplify local and systemic immune responses against cancer.
The rationale is scientifically compelling: PULSAR's adaptive fractionation schedule may optimize the immunogenic cell death window, making tumors more visible to the immune system, while IMSA101 could further amplify that immune recognition. Adding ICI therapy to block inhibitory checkpoints completes a mechanistic triad designed to convert a local radiation event into a systemic anti-tumor immune response, sometimes called the abscopal effect.
Unfortunately, the trial was terminated before reaching its enrollment target, closing in November 2024 with only 16 participants. No efficacy or safety outcome data are available in the public record at this time. Early termination may reflect feasibility challenges, funding constraints, or preliminary safety signals — the specific reason is not disclosed in the available abstract.
For clinicians and researchers, this trial underscores both the promise and difficulty of combination immuno-radiation strategies. Oligoprogression remains an underserved clinical scenario, and while this particular study could not generate definitive answers, the mechanistic hypothesis behind PULSAR plus STING agonism plus ICI remains scientifically active and warrants continued investigation in better-resourced trials.
Key Findings
- Trial combined PULSAR adaptive radiation, checkpoint inhibitors, and IMSA101 STING agonist for oligoprogressive solid tumors.
- Only 16 patients were enrolled before the trial was terminated in November 2024.
- No efficacy or safety outcome data are publicly available from this terminated study.
- The STING agonist plus radiation plus ICI combination hypothesis remains scientifically unproven in this setting.
- Oligoprogression after prior therapy is a growing clinical challenge with no established standard approach.
Methodology
Phase 2, open-label, multicenter, randomized design comparing PULSAR-ICI plus IMSA101 versus PULSAR-ICI alone. The trial enrolled patients with oligoprogressive solid tumors following prior anti-cancer therapy. The study was terminated early with only 16 participants, far below a typical Phase 2 enrollment threshold needed for meaningful statistical analysis.
Study Limitations
The trial was terminated early with only 16 patients enrolled, making it underpowered to draw any conclusions about safety or efficacy. The summary is based on the abstract and ClinicalTrials.gov registration only, as full data are not publicly available. The reason for trial termination is not disclosed, limiting understanding of whether safety, feasibility, or sponsor decisions drove closure.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.